StockTipsArenaBeta

SELL Zydus Lifesciences Limited — Investec India

SELLZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byInvestec IndiaHorizon: NA (inferred 1 year)12 Aug 2026via NDTV Profit (Live)

Entry₹1,190Inferred
Target₹1,090
Total upside +8.40% (call closed)
Stop lossNot given
Exit₹1,09016 Sept 2026, 12:09 pm
Target hit+8.40%0.00%upside left
Follow Investec India for new callsGet alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 7 active Long-term calls on ZYDUSLIFESee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 16 Sept 2026
5 supporting13 neutral26 opposing
Supports the SELL call (5)

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·12 Aug · 1mo ago

Neutral / worth noting (13)

Zydus Pharmaceuticals USA Inc., a subsidiary of Zydus Lifesciences, has agreed to pay USD 5.9 million to settle litigation in the US District Court for the Eastern District of Pennsylvania. The settle

BSE · Company Update·5 Sept · 1w ago

(opens in new tab)
Weighs against the SELL call (26)

India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth

NewsNdtv-Profit·9 Sept · 6d ago

(opens in new tab)

Zydus Lifesciences announced positive topline results from the completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg for MASH.

BSE · Company Update·31 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

NewsNdtv-Profit·27 Aug · 3w ago

(opens in new tab)

Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection

NewsNdtv-Profit·21 Aug · 4w ago

(opens in new tab)

Zydus Lifesciences gets USFDA approval for generic Ascorbic Acid Injection

NewsCnbc-Tv18·21 Aug · 4w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Investec India

Every call and its outcome